Du-Shieng Chien, President & CEO of TaiRx, a Taiwan-based biopharmaceutical company focused on unmet medical needs, provides insights into the recent development of CVM 1118, a revolutionary cancer treatment targeting breakthrough mechanisms to tackle tumor development and the first drug of its kind to have already started clinical trials in the US, as well as an update on Rexis®’ advancement, TaiRx’s groundbreaking treatment for sepsis that could soon enter the global market.
Could you provide our international readers with a brief introduction to TaiRx and explain why you decided to take the leap of faith to start your own biotech company?
"CVM 1118 is a completely New Chemical Entity (NCE) in the oncology area, which is targeting breakthrough mechanisms to tackle tumor development."
